October 08, 2019
CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA, October 8, 2019 – The Broad Institute of MIT and Harvard and Calico Life Sciences today announced an extension of their partnership focused on the biology and genetics of aging as well as early-stage drug discovery. The partnership was originally announced in March 2015 and this renewed agreement will extend the relationship until September 2024. Terms of the deal were not disclosed.
“Over the past few years, we have made excellent progress on our shared drug discovery initiatives with the Broad, advancing a number of key projects from target discovery toward clinical development,” said Arthur D. Levinson, Ph.D., Founder and CEO of Calico. “The Broad is renowned for its substantial genetics and biology expertise, enabling countless fundamental advances from Broad scientists across many age-related diseases. They are a terrific and productive partner, and we are looking forward to bringing forward additional discovery programs in aging and age-related diseases with the extension of our collaboration.”
“We’re delighted to continue this partnership on discovery and therapeutics with the extraordinary scientists at Calico. Calico has been a superb and thoughtful partner, committed to scientific excellence,” said Eric Lander, President and Director of the Broad Institute. “Patients desperately need new therapies to combat diseases of aging, such as cancer, and we are confident this collaboration will propel progress.”
About the Broad Institute of MIT and Harvard
The Eli and Edythe L. Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.
Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to broadinstitute.org.
Calico (Calico Life Sciences LLC) is an Alphabet-founded research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. Calico will use that knowledge to devise interventions that enable people to lead longer and healthier lives.
To learn more about Calico, visit www.calicolabs.com